ABIVAX Société Anonyme (ABVX)
| Market Cap | 7.78B +1,906.4% |
| Revenue (ttm) | 5.67M -59.8% |
| Net Income | -383.03M |
| EPS | -5.22 |
| Shares Out | 79.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,916,692 |
| Open | 93.30 |
| Previous Close | 90.15 |
| Day's Range | 92.65 - 105.65 |
| 52-Week Range | 5.69 - 148.83 |
| Beta | -0.19 |
| Analysts | Buy |
| Price Target | 149.09 (+42.09%) |
| Earnings Date | Mar 23, 2026 |
About ABVX
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Financial Performance
In 2025, ABIVAX Société Anonyme's revenue was 4.57 million, a decrease of -63.22% compared to the previous year's 12.43 million. Losses were -336.10 million, 90.7% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ABVX stock is "Buy." The 12-month stock price target is $149.09, which is an increase of 42.09% from the latest price.
News
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against ABIVAX Societe Anonyme (ABVX)
New York, New York--(Newsfile Corp. - June 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ABIVAX Societe Anonyme ("ABIVAX Societe Anonyme") (NASDAQ: ABVX) c...
Spyre Therapeutics price target raised to $115 from $102 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Spyre Therapeutics (SYRE) to $115 from $102 and keeps a Buy rating on the shares. Competitor Abivax (ABVX) traded down 30% since…
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $ABVX--ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm.
This Is Why Abivax Stock (ABVX) Is Up Today
Abivax stock was up after one of the company’s clinical trials was a success.
Abivax price target lowered to $136 from $176 at Wolfe Research
Wolfe Research lowered the firm’s price target on Abivax (ABVX) to $136 from $176 and keeps an Outperform rating on the shares. The firm believes the stock is being “over…
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
Jefferies downgraded Abivax from Buy to Hold and slashed its price target by nearly 44% after rare cancer cases emerged in the company's Phase 3 ulcerative colitis trial -- shares more than 40% of the...
Abivax price target lowered to $135 from $140 at Truist
Truist lowered the firm’s price target on Abivax (ABVX) to $135 from $140 and keeps a Buy rating on the shares. The company reported topline maintenance data from the phase…
Abivax price target lowered to $132 from $145 at Morgan Stanley
Morgan Stanley analyst Judah Frommer lowered the firm’s price target on Abivax (ABVX) to $132 from $145 and keeps an Overweight rating on the shares. Although efficacy data from the…
Wedbush upgrades Abivax to Neutral, lowers target to $90
As previously reported, Wedbush upgraded Abivax (ABVX) to Neutral from Underperform with a price target of $90, down from $110. The firm notes the company reported placebo-adjusted maintenance clinica...
Abivax upgraded to Neutral from Underperform at Wedbush
Wedbush upgraded Abivax (ABVX) to Neutral from Underperform with a price target of $90, down from $110.
Abivax price target raised to $187 from $131 at Citizens
Citizens raised the firm’s price target on Abivax (ABVX) to $187 from $131 and keeps an Outperform rating on the shares. Abivax reported Phase 3 maintenance trial results showing that…
Abivax downgraded to Hold from Buy at Jefferies
Jefferies analyst Faisal Khurshid downgraded Abivax (ABVX) to Hold from Buy with a price target of $90, down from $160. The company’s key ABTECT maintenance trial in ulcerative colitis showed…
Abivax Shares Plunge After Company Reports Adverse Events in Key Drug Trial
The biotech said some patients developed cancer in a late-stage clinical trial for the bowel-disease drug that were unrelated to the treatment.
Abivax stock crashes as safety fears overshadow bowel disease drug trial win
Abivax shares fell 31% even after the French biotech reported strong late-stage data for obefazimod, its experimental treatment for ulcerative colitis. The once-daily oral therapy met the main goal an...
Abivax shares sink after key trial results for inflammatory bowel drug
Abivax shares tumbled on Tuesday after the French biotech reported late-stage data for its experimental inflammatory bowel drug, with investors focusing on safety concerns even as the treatment showe...
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Abivax's inflammatory bowel drug meets main goal of late stage trial
Abivax said on Monday its experimental drug for patients with ulcerative colitis, a type of chronic inflammatory disease, met the main goal of a closely watched late-stage trial.
Abivax announces ABTECT trial meets primary, secondary endpoints
Abivax (ABVX) announced topline results from the Phase 3 ABTECT maintenance trial evaluating obefazimod, its investigational oral, first-in-class miR-124 enhancer, in adults with moderately to severel...
ABIVAX Société Anonyme Transcript: Study result
The phase III ABTECT maintenance trial in ulcerative colitis showed both 25 mg and 50 mg obefazimod achieved best-in-class clinical and endoscopic remission rates with a favorable safety profile over 44 weeks, outperforming current therapies and supporting dose flexibility for future use.
ABIVAX Société Anonyme Press release: Study result
ABIVAX Société Anonyme issued a press release on June 1, 2026, disclosing material business information to investors.